Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Identification and discrimination of binding sites of an organoruthenium anticancer complex to single-stranded oligonucleotides by mass spectrometry.

Liu S, Wu K, Zheng W, Zhao Y, Luo Q, Xiong S, Wang F.

Analyst. 2014 Sep 21;139(18):4491-6. doi: 10.1039/c4an00807c.

PMID:
25028701
2.

Competitive binding sites of a ruthenium arene anticancer complex on oligonucleotides studied by mass spectrometry: ladder-sequencing versus top-down.

Wu K, Hu W, Luo Q, Li X, Xiong S, Sadler PJ, Wang F.

J Am Soc Mass Spectrom. 2013 Mar;24(3):410-20. doi: 10.1007/s13361-012-0539-z. Epub 2013 Feb 13.

PMID:
23404464
3.

Thymines in single-stranded oligonucleotides and G-quadruplex DNA are competitive with guanines for binding to an organoruthenium anticancer complex.

Wu K, Liu S, Luo Q, Hu W, Li X, Wang F, Zheng R, Cui J, Sadler PJ, Xiang J, Shi Q, Xiong S.

Inorg Chem. 2013 Oct 7;52(19):11332-42. doi: 10.1021/ic401606v. Epub 2013 Sep 11.

PMID:
24024654
4.

Mechanism of interstrand migration of organoruthenium anticancer complexes within a DNA duplex.

Wu K, Luo Q, Hu W, Li X, Wang F, Xiong S, Sadler PJ.

Metallomics. 2012 Feb;4(2):139-48. doi: 10.1039/c2mt00162d. Epub 2012 Jan 20.

PMID:
22262368
5.

Competition between glutathione and DNA oligonucleotides for ruthenium(II) arene anticancer complexes.

Wang F, Xu J, Wu K, Weidt SK, Mackay CL, Langridge-Smith PR, Sadler PJ.

Dalton Trans. 2013 Mar 7;42(9):3188-95. doi: 10.1039/c2dt32091f. Epub 2012 Oct 18.

PMID:
23076358
6.

Organometallic ruthenium(II) diamine anticancer complexes: arene-nucleobase stacking and stereospecific hydrogen-bonding in guanine adducts.

Chen H, Parkinson JA, Parsons S, Coxall RA, Gould RO, Sadler PJ.

J Am Chem Soc. 2002 Mar 27;124(12):3064-82.

PMID:
11902898
7.

Ruthenation of duplex and single-stranded d(CGGCCG) by organometallic anticancer complexes.

Liu HK, Wang F, Parkinson JA, Bella J, Sadler PJ.

Chemistry. 2006 Aug 7;12(23):6151-65.

PMID:
16807967
8.

Use of ion mobility mass spectrometry and a collision cross-section algorithm to study an organometallic ruthenium anticancer complex and its adducts with a DNA oligonucleotide.

Williams JP, Lough JA, Campuzano I, Richardson K, Sadler PJ.

Rapid Commun Mass Spectrom. 2009 Nov;23(22):3563-9. doi: 10.1002/rcm.4285.

PMID:
19844963
9.

Organometallic ruthenium anticancer complexes inhibit human glutathione-S-transferase π.

Lin Y, Huang Y, Zheng W, Wang F, Habtemariam A, Luo Q, Li X, Wu K, Sadler PJ, Xiong S.

J Inorg Biochem. 2013 Nov;128:77-84. doi: 10.1016/j.jinorgbio.2013.07.029. Epub 2013 Jul 25.

PMID:
23942162
10.

Transferrin serves as a mediator to deliver organometallic ruthenium(II) anticancer complexes into cells.

Guo W, Zheng W, Luo Q, Li X, Zhao Y, Xiong S, Wang F.

Inorg Chem. 2013 May 6;52(9):5328-38. doi: 10.1021/ic4002626. Epub 2013 Apr 15.

PMID:
23586415
11.

Anticancer activity and DNA binding of a bifunctional Ru(II) arene aqua-complex with the 2,4-diamino-6-(2-pyridyl)-1,3,5-triazine ligand.

Busto N, Valladolid J, Martínez-Alonso M, Lozano HJ, Jalón FA, Manzano BR, Rodríguez AM, Carrión MC, Biver T, Leal JM, Espino G, García B.

Inorg Chem. 2013 Sep 3;52(17):9962-74. doi: 10.1021/ic401197a. Epub 2013 Aug 20.

PMID:
23957818
12.

DNA interactions of monofunctional organometallic ruthenium(II) antitumor complexes in cell-free media.

Novakova O, Chen H, Vrana O, Rodger A, Sadler PJ, Brabec V.

Biochemistry. 2003 Oct 7;42(39):11544-54.

PMID:
14516206
13.

Ruthenium versus platinum: interactions of anticancer metallodrugs with duplex oligonucleotides characterised by electrospray ionisation mass spectrometry.

Groessl M, Tsybin YO, Hartinger CG, Keppler BK, Dyson PJ.

J Biol Inorg Chem. 2010 Jun;15(5):677-88. doi: 10.1007/s00775-010-0635-0. Epub 2010 Mar 7.

PMID:
20213306
14.

Binding of an organo-osmium(II) anticancer complex to guanine and cytosine on DNA revealed by electron-based dissociations in high resolution Top-Down FT-ICR mass spectrometry.

Wootton CA, Sanchez-Cano C, Liu HK, Barrow MP, Sadler PJ, O'Connor PB.

Dalton Trans. 2015 Feb 28;44(8):3624-32. doi: 10.1039/c4dt03819c.

PMID:
25650025
15.
16.

Modulating the Anticancer Activity of Ruthenium(II)-Arene Complexes.

Clavel CM, Păunescu E, Nowak-Sliwinska P, Griffioen AW, Scopelliti R, Dyson PJ.

J Med Chem. 2015 Apr 23;58(8):3356-65. doi: 10.1021/jm501655t. Epub 2015 Apr 7.

PMID:
25812075
17.

Development of Arene Ruthenium Antitumor Complexes.

Su W, Tang Z, Li P.

Mini Rev Med Chem. 2016;16(10):787-95. Review.

PMID:
27161008
18.
19.

Quantification of bindings of organometallic ruthenium complexes to GSTπ by mass spectrometry.

Lin Y, Huang Y, Zheng W, Wu K, Luo Q, Zhao Y, Xiong S, Wang F.

J Inorg Biochem. 2015 May;146:44-51. doi: 10.1016/j.jinorgbio.2015.02.015. Epub 2015 Mar 2.

PMID:
25769011
20.

Influence of PPh₃ moiety in the anticancer activity of new organometallic ruthenium complexes.

Sáez R, Lorenzo J, Prieto MJ, Font-Bardia M, Calvet T, Omeñaca N, Vilaseca M, Moreno V.

J Inorg Biochem. 2014 Jul;136:1-12. doi: 10.1016/j.jinorgbio.2014.03.002. Epub 2014 Mar 15.

PMID:
24690555

Supplemental Content

Support Center